Unusual manifestation of tuberculosis in an ulcerative colitis patient treated with infliximab

Česká verzia

Authors: Dombrovská K. ¹; Hrabovský V. ^1,2; Štefaňáková Z. ¹; Škrobánková M. ^1,2; Svoboda P. ^1,2
Published in the journal: Gastroent Hepatol 2019; 73(4): 339-344
Category:
doi: https://doi.org/10.14735/amgh2019339

Summary

Tumor necrosis factor alpha (TNF-α) inhibitors are very potent treatments for ulcerative colitis (UC). However, infectious complications, including tuberculosis (TB), are a major risk with these medications. This study aimed to present a case report of a TB patient treated with infliximab (IFX) and to summarize recent information about TB in the Czech Republic. A refractory UC patient treated with IFX was repeatedly hospitalized due to infectious complications. Following extensive differential diagnosis, TB infection with predominant brain involvement was diagnosed. The major cause of TB infection during anti-TNF (a-TNF) therapy is probably reactivation of the latent form. TNF plays an essential role in the pathogenesis of TB infection, and the host immune system fails when TNF is blocked. Therefore, TB usually develops soon after initiation of a-TNF therapy, and prophylactic antituberculotic treatment is often ineffective. The extrapulmonary form is more common than the pulmonary form. TB is an important complication of a-TNF treatment. Preventive examinations prior to initiation of a-TNF therapy only reduce the disease incidence. One possible solution is consistent implementation or further tightening of professional guidelines.

Doručeno/Submitted: 24. 3. 2019

Přijato/Accepted: 18. 6. 2019

MUDr. Martina Škrobánková

Interní klinika LF OU a FN Ostrava

17. listopadu 1790

708 00 Ostrava-Poruba

martinaskrobankova@email.cz

Keywords:

infliximab – Ulcerative colitis – tuberculosis

Zdroje

1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23): 2462–2476. doi: 10.1056/NEJMoa050516.

2. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137 (4): 1250–1260. doi: 10.1053/j.gastro.2009.06.061.

3. Holdam AS, Bager P, Dahlerup JF. Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. Scand J Gastroenterol 2016; 51 (6): 706–711. doi: 10.3109/ 00365521.2015.1136352.

4. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání. Gastroent Hepatol 2016; 70 (1): 11–27. doi: 10.14735/amgh201611.

5. Buc M. Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases. Vnitr Lek 2018; 64 (3): 280–289.

6. Salmon-Ceron D, Tubach F, Lortholary O et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70 (4): 616–623. doi: 10.1136/ard.2010.137 422.

7. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2 (11): 602–610. doi: 10.1038/ncprheum 0336.

8. Bekker LG, Freeman S, Murray PJ et al. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001; 166 (11): 6728–6734. doi: 10.4049/jimmunol.166.11. 6728.

9. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60 (7): 1884–1894. doi: 10.1002/art.24632.

10. Borekci S, Atahan E, Demir Yilmaz D et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration 2015; 90 (3): 191–198. doi: 10.1159/000434684.

11. Elbek O, Uyar M, Aydin N et al. Increased risk of tuberculosis in patients treated with anti tumor necrosis factor alpha. Clin Rheumatol 2009; 28 (4): 421–426. doi: 10.1007/ s10067-008-1067-x.

12. Cagatay T, Bingol Z, Kıyan E et al. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: tuberculin skin test conversion and tuberculosis risk. Clin Respir J 2018; 12 (4): 1668–1675. doi: 10.1111/crj.12726.

13. ÚZIS ČR. Tuberkuloza a respirační nemoci. 2014. [online]. Dostupné na: https: //www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/tuberkuloza-cr.

14. Bortlík M, Ďuricová D, Douda T et al. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol 2019; 73 (1): 11–24. doi: 10.14735/amgh201911.

15. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098–1104. doi: 10.1056/NEJMoa011 110.

16. Hanta I, Ozbek S, Kuleci S et al. Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNFα therapy: tuberculin skin test versus IFN-γ assay. Rheumatol Int 2012; 32 (11): 3599–3603. doi: 10.1007/s00296-011-2243-x.

17. Lin J, Ziring D, Desai S et al. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126 (1): 13–30. doi: 10.1016/j.clim.2007.08.012.

18. Calzada-Hernández J, Anton-López J, Bou-Torrent R et al. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study. Pediatr Rheumatol 2015; 13: 54. doi: 10.1186/s12969-015-0054-4.

19. Ng SC, Hilmi IN, Blake A et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis 2018; 24 (11): 2431–2441. doi: 10.1093/ibd/izy 153.

20. Lee JW, Choi CH, Park JH. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res 2016; 14 (2): 146–151. doi: 10.5217/ir.2016.14.2. 146.

21. Homolka J. Doporučení pro biologickou léčbu preparáty blokujícími účinek TNF alfa. 2016. [online]. Dostupné na: http: //www.pneumologie.cz/guidelines/.

22. Vencovský J. Výbor České revmatologické společnosti. Bezpečnost biologické léčby – doporučení České revmatologické společnosti. Čes Revmatol 2009; 17 (3): 146–160.